- Home
- NEWP vs ALDX Comparison
NEWP vs ALDX Comparison
Compare NEWP & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWP
- ALDX
- Stock Information
- Founded
- NEWP 1972
- ALDX 2004
- Country
- NEWP Canada
- ALDX United States
- Employees
- NEWP N/A
- ALDX N/A
- Industry
- NEWP
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- NEWP
- ALDX Health Care
- Exchange
- NEWP Nasdaq
- ALDX Nasdaq
- Market Cap
- NEWP 259.4M
- ALDX 270.7M
- IPO Year
- NEWP N/A
- ALDX 2014
- Fundamental
- Price
- NEWP $1.45
- ALDX $4.81
- Analyst Decision
- NEWP
- ALDX Strong Buy
- Analyst Count
- NEWP 0
- ALDX 2
- Target Price
- NEWP N/A
- ALDX $9.50
- AVG Volume (30 Days)
- NEWP 287.8K
- ALDX 1.2M
- Earning Date
- NEWP 09-23-2025
- ALDX 08-12-2025
- Dividend Yield
- NEWP N/A
- ALDX N/A
- EPS Growth
- NEWP N/A
- ALDX N/A
- EPS
- NEWP N/A
- ALDX N/A
- Revenue
- NEWP N/A
- ALDX N/A
- Revenue This Year
- NEWP N/A
- ALDX N/A
- Revenue Next Year
- NEWP N/A
- ALDX $29.89
- P/E Ratio
- NEWP N/A
- ALDX N/A
- Revenue Growth
- NEWP N/A
- ALDX N/A
- 52 Week Low
- NEWP $0.93
- ALDX $1.14
- 52 Week High
- NEWP $2.05
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- NEWP 39.89
- ALDX 53.97
- Support Level
- NEWP $1.61
- ALDX $5.21
- Resistance Level
- NEWP $1.71
- ALDX $5.35
- Average True Range (ATR)
- NEWP 0.10
- ALDX 0.33
- MACD
- NEWP -0.04
- ALDX -0.12
- Stochastic Oscillator
- NEWP 13.18
- ALDX 40.70
About NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.